Reaction

Muscle Rupture reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,826 reports · 62 co-occurring drugs

As of the last recalculation, Muscle Rupture appears in 3,826 FAERS reports alongside 62 co-occurring drug terms. The strongest observed disproportionality signal is CIPROFOLXACIN (PRR 15.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ciprofolxacin	198	15.8	15.9
Ciprofloxacin Tablets	198	15.8	15.8
Ciprofloxacin	224	14.0	14.1
Ciprofloxacin Hydrochloride	235	13.9	14.0
Calcium, Magnesium, Potassium, And Sodium Oxybates	12	7.6	7.6
Ciprofloxacin Hydrochloride And Hydrocortisone	27	7.1	7.1
Ezetimibe	92	6.8	6.8
Atorvastatin Calcium, Film Coated	79	6.2	6.2
Levofloxacin	63	5.8	5.8
Levofloxacin In 5% Dextrose	63	5.8	5.8
Desloratadine	11	5.6	5.6
Pravastatin Sodium	20	5.5	5.5
Simvastatin	236	5.4	5.4
Thyroid, Porcine	10	5.1	5.1
Ezetimibe And Simvastatin	14	5.0	5.0
Pramipexole	14	5.0	5.0
Rosuvastatin	180	5.0	5.0
Dolutegravir Sodium	8	4.8	4.8
Nebivolol	14	4.8	4.8
Inclisiran	7	4.8	4.8
Upadacitinib	68	4.6	4.6
Testosterone	19	4.4	4.4
Salmeterol Xinafoate	7	4.4	4.4
Risankizumab-Rzaa	64	4.3	4.3
Atorvastatin Calcium	188	4.3	4.3
Infliximab-Dyyb	22	4.1	4.1
Prasugrel Hydrochloride	7	3.8	3.8
Clopidogrel Bisulfate	68	3.7	3.7
Quinapril Hydrochloride	5	3.5	3.5
Amlodipine Besylate And Valsartan	7	3.4	3.4
Tizanidine	15	3.4	3.4
Sevelamer Carbonate	7	3.3	3.3
Instalax Polyethylene Glycol 3350	7	3.1	3.1
Nebivolol Hydrochloride	19	3.1	3.1
Alirocumab	14	3.0	3.0
Polyethylene Glycol 400	7	3.0	3.0
Armodafinil	11	2.8	2.8
Adalimumab	344	2.8	2.8
Insulin Degludec	12	2.8	2.8
Diroximel Fumarate	6	2.7	2.7
Cabotegravir	4	2.7	2.7
Sodium Oxybate	32	2.7	2.7
Elexacaftor, Tezacaftor, And Ivacaftor	6	2.6	2.6
Naltrexone Hydrochloride And Bupropion Hydrochloride	4	2.6	2.6
Tofacitinib	85	2.5	2.5
Dexlansoprazole	19	2.5	2.5
Vilazodone Hydrochloride	4	2.4	2.4
Asfotase Alfa	4	2.2	2.2
Ixazomib	11	2.1	2.1
Fremanezumab-Vfrm	4	1.9	1.9
Tolvaptan	5	1.9	1.9
Eptinezumab-Jjmr	3	1.8	1.8
Naltrexone	10	1.8	1.8
Rimegepant Sulfate	4	1.7	1.7
Ravulizumab	4	1.6	1.6
Abiraterone	4	1.6	1.6
Emicizumab	3	1.3	1.3
Natalizumab	40	1.2	1.2
Dornase Alfa	4	1.1	1.1
Evolocumab	29	1.0	1.0
Guselkumab	6	0.9	0.9
Nirmatrelvir And Ritonavir	6	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.